Character Biosciences is committed to pioneering precision medicine solutions for polygenic diseases. Our growing therapeutic pipeline is focused on developing groundbreaking treatments aimed at addressing diseases with significant unmet medical needs. Our research teams are rapidly advancing preclinical programs with a primary focus on dry Age-Related Macular Degeneration (AMD) and Primary Open-Angle Glaucoma (POAG).
CTX203 is a potential first-in-class lipid-modulating agent designed to prevent irreversible retinal cell death and vision loss. Based on human genetics evidence, CTX203 is a de novo designed apolipoprotein A1 mimetic peptide with a dual-acting mechanism: (1) stabilization of ABCA1 at the plasma membrane to enhance intracellular lipid efflux and (2) extracellular lipid packaging and clearance. In addition, Character has developed and plans to deploy a proprietary lipid pathway-specific polygenic risk score to identify patients more likely to progress quickly and to respond to lipid-modulating therapy.
Character Bio is currently running IND-enabling studies, with clinical trial initiation planned for 2024.
CTX114 is a novel complement inhibitor designed to slow down the rate of retinal cell death and vision loss. Based on human genetics evidence, CTX114 is designed for enhanced protection of retinal surfaces from complement activation. Character Bio has generated a compelling preclinical data package demonstrating CTX114’s potential best-in-class approach to complement inhibition. Character has also developed a proprietary complement pathway- specific polygenic risk score to identify patients more likely to progress quickly and to respond to complement-directed therapy.
Character Bio is currently running IND-enabling studies, with clinical trial initiation planned for 2025.
CTX203 is a potential first-in-class lipid-modulating agent designed to prevent irreversible retinal cell death and vision loss. Based on human genetics evidence, CTX203 is a de novo designed apolipoprotein A1 mimetic peptide with a dual-acting mechanism: (1) stabilization of ABCA1 at the plasma membrane to enhance intracellular lipid efflux and (2) extracellular lipid packaging and clearance. In addition, Character has developed and plans to deploy a proprietary lipid pathway-specific polygenic risk score to identify patients more likely to progress quickly and to respond to lipid-modulating therapy.
Character Bio is currently running IND-enabling studies, with clinical trial initiation planned for 2024.
CTX114 is a novel complement inhibitor designed to slow down the rate of retinal cell death and vision loss. Based on human genetics evidence, CTX114 is designed for enhanced protection of retinal surfaces from complement activation. Character Bio has generated a compelling preclinical data package demonstrating CTX114’s potential best-in-class approach to complement inhibition. Character has also developed a proprietary complement pathway- specific polygenic risk score to identify patients more likely to progress quickly and to respond to complement-directed therapy.
Character Bio is currently running IND-enabling studies, with clinical trial initiation planned for 2025.
